Edesa Biotech (EDSA) News
NASDAQ: EDSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
2.00-0.175 (-8.05%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EDSA news summary
We found 7 recent headlines mentioning Edesa Biotech (EDSA): 3 in the past week and 6 in the past 30 days, most often from GlobeNewswire, Nasdaq. EDSA is making an outsized move today, down 8.05% at $2.00, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Edesa Biotech, Inc. Announces EU Orphan Designation for Paridiprubart", was published by Nasdaq on Nov 17, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Edesa Biotech headlines
- Edesa Biotech, Inc. Announces EU Orphan Designation for ParidiprubartOn November 17, 2026, Edesa Biotech, Inc. (the “Company”) announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment…Nasdaq
- Edesa Receives EU Orphan Drug Designation For ARDS Therapy Paridiprubart(RTTNews) - Edesa Biotech, Inc. (EDSA) announced that the European Commission (EC) has granted orphan designation to paridiprubart for the treatment of acute respiratory distress syndrome.NasdaqEDSA, ET
- Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European CommissionTORONTO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…GlobeNewswire
- Edesa Biotech Partners With KYORIN In Japan Deal Worth Up To $140 Million Plus Royalties; Stock Up(RTTNews) - Edesa Biotech, Inc. (EDSA) has entered into an exclusive licensing and collaboration agreement with KYORIN Pharmaceutical to develop and commercialize paridprubart in Japan for the…NasdaqEDSA, LEN.B
- Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in JapanTORONTO and TOKYO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for…GlobeNewswire
- Edesa Biotech to Present at Guggenheim Healthcare Innovation ConferenceTORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…GlobeNewswire
- Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo StudyTORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory…GlobeNewswire